Radiation internal dosimetry in radioimmunotherapy using 131I-rituximab
暂无分享,去创建一个
Radioimmunotherapy (RIT) is a promising approach for targeted therapy to treat intractable cancer because radionuclides are delivered more selective to tumor using monoclonal antibody, RIT can be used clinical practice with administration of murine anti-CD20. In this study, the absorbed dose of total body and red marrow of patient enrolled in RIT study was calculated.
[1] D. Rizzieri,et al. Radioimmunotherapy for Non-Hodgkin's Lymphoma. , 2005, Clinical medicine & research.
[2] J. Bouček,et al. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. , 2003, Cancer biotherapy & radiopharmaceuticals.